Tag Archives | targeted therapy

Rayno Life Science: Biotech Stocks Hit A Wall At New Highs Up 40% YTD

 Red Tape Today Means Caution-Take Some Off XBI at $167.83 Off 2% Traders, investors, executives even pension funds are thrilled with biotech investing as the stock group rolls on to new highs this month. What may not be appreciated is the 20% move off the October 16 bottom when gloom and doom reached its nadir […]

Continue Reading 0

Rayno Life Science Stocks: Up 30%+ YTD After A Volatile October

Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from the FED and a potential global economic slowdown. But fears […]

Continue Reading

Bio Investor Forum #2: T-Cell Therapies and Cancer Targets

Genetically Modified T-cells: Gene Therapy Is Back! Here are some quick notes and an overview of the companies at Bio: Immuno-Oncology  is one of the hottest new areas of biopharmaceutical development and on October 7  BIO presented a Therapeutic Session on “T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets”. […]

Continue Reading

Rayno Life Science Performance: Up 21%+ YTD…FBT, GILD, ILMN

Biotechs Continue To Lead The Market NASDAQ registered its third day of gains up 2.38% for the period and life science stocks followed. The NAZ is now up 3.34% YTD. Biotech stocks are way ahead of the market  YTD with our top ETF pick (FBT) up 31% YTD and 3.66% over five days.The IBB is […]

Continue Reading

Trading A Bottom in Small Cap Life Science Stocks …Update 11/5

11/15/14  Speculative Small Cap Stocks-Stay Away Unless Your Are A Trader Nice profits were booked on our recent small cap picks but today the sell-off was “pronounced”: Celldex (CLDX) was down 21% to $13.10 after hitting a high near $18 on October 31. GlycoMimetics (GLYC) was up 2.14% to $7.62 more than 15% above our […]

Continue Reading